Molecular mechanisms of interleukin-10-mediated inhibition of NF-κB activity: A role for p50

Clinical and Experimental Immunology

Volumn 135, Issue 1, 2004, Pages 64-73

  Driessler, F ^a   Venstrom, K ^b   Sabat, R ^a   Asadullah, K ^a   Schottelius, A J ^a,c  

^a BAYER PHARMA AG   (Germany)

^b Res Business Area Dermatology USA   (United States)

^c BAYER AG   (Germany)

Author keywords

Inflammation; Interleukin 10; Macrophages; Monocytes; NF B; Signal transduction

Indexed keywords

CYTOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 2 ALPHA; PROTEIN P50; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA BINDING; DNA TRANSCRIPTION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL HOST; GENE REPRESSION; MACROPHAGE; MECHANOTRANSDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT;

ANIMALS; CELLS, CULTURED; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED STRAINS; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROTEIN PRECURSORS; RECOMBINANT PROTEINS; TRANSCRIPTION FACTOR RELA; TRANSLOCATION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0347949510     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02342.x     Document Type: Article

References (45)

1. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-65.
2. Kuhn R, Lohler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
3. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5:1461-71.
4. Herfarth H, Mohanty S, Rath H et al. Interleukin-10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996; 39:836-45.
5. Herfarth H, Bocker U, Janardhanam R et al. Subtherapeutic corticosteroids potentiate the ability of interleukin-10 to prevent chronic inflammation in rats. Gastroenterology 1998; 115:856-65.
6. Walmsley M, Katsikis P, Abney E et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39:495-3.
7. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24:1434-40.
8. Van Laethem JL, Marchant A, Delvaux A et al. Interleukin-10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995; 108:1917-22.
9. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169-75.
10. Gerard C, Bruyns C, Marchant A et al. Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-50.
11. Schreiber S, Heinig T, Thiele HG et al. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-44.
12. van Deventer S, Elson C, Fedorak R. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Crohn's Dis Study Group Gastroenterol 1997; 113:383-9.
13. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101:783-94.
14. Baldwin A. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-83.
15. Makarov SS. NF-kappa B in rheumatoid arthritis, a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001; 3:200-6.
16. Schottelius AJ, Baldwin A. A role for transcription factor NF-κB in intestinal inflammation. Int J Colored Dis 1999; 14:18-28.
17. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. New Engl J Med 1999; 341:1817-28.
18. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, Brennan F, Feldmann M. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci USA 1998; 95:8211-5.
19. Yamamoto Y, Gaynor RB. Therapeutic potential of NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-42.
20. Lin L, DeMartino GN, Greene WC. Cotranslational dimerization of the Rel homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for effective p50 production. EMBO J 2000; 19:4712-22.
21. Finco T, Baldwin A. Mechanistic aspects of NF-kappa B regulation, the emerging role of phosphorylation and proteolysis. Immunity 1995; 3:263-72.
22. Schmitz M, dos Santos Silva MA, Baeuerle PA. Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J Biol Chem 1995; 270:15576-84.
23. Finco TS, Beg AA, Baldwin AS Jr. Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. Proc Natl Acad Sci USA 1994; 91:11884-8.
24. Baer M, Dillner A, Schwartz RC et al. Tumor necrosis factor alpha transcription in macrophages is attenuated by an autrocrine factor that preferentially induces NF-kappa B p50. Mol Cell Biol 1998; 18:5678-89.
25. Cassatella MA, Gasperini S, Bovolenta C et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 1999; 94:2880-9.
26. Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol 2002; 168:6404-11.
27. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donelly RP, Larner AC, Finbloom DS. Interleukin-10 inhibitis expression of both interferon alpha-and inteferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999; 93:1456-63.
28. Denys A, Udalova I, Smith C, Williams LM, Ciesielski CJ, Campbell J, Andrews C, Kwaitkowski D, Foxwell BMJ. Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-κB in primary human macrophages. J Immunol 2002; 168:4837-45.
29. Wang P, Wu P, Siegel MI et al. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270:9558-63.
30. Dokter W, Koopmans S, Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation. Leukemia 1996; 10:1308-16.
31. Romano MF, Lamberti A, Petrella A et al. IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J Immunol 1996; 156:2119-23.
32. Clarke CJP, Hales A, Hunt A et al. IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol 1998; 28:1719-26.
33. Schottelius AJ, Mayo MW, Sartor RB et al. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274:31868-74.
34. Sha WC, Liou HC, Tuomanen EL et al. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1999; 80:321-30.
35. Vanden Berghe W, Vermeulen L, De Wilde G et al. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60:1185-95.
36. Shi MM, Chong I, Godleski J et al. Regulation of macrophage inflammatory protein-2 gene expression by oxidative stress in rat alveolar macrophages. Immunology 1999; 97:309-15.
37. Ziegler-Heitbrock HWL, Petersmann I, Frankenberger M. p50 (NF-kappa B1) is upregulated in LPS tolerant P388D1 murine macrophages. Immunobiology 1997; 198:73-80.
38. Heissmeyer V, Krappmann D, Wulczyn FG et al. NF-kappa B p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J 1999; 18:4766-78.
39. Randow F, Syrbe U, Meisel C et al. Mechanism of endotoxin desensitization: involvement of interleukin-10 and transforming growth factor beta. J Exp Med 1995; 181:1887-92.
40. Blank V, Kourilsky P, Israel A. Cytoplasmic retention, DNA-binding and processing of the NF-kappaB p50 precursor are controlled by a small region in its C-terminus. EMBO J 1991; 10:4159-67.
41. Henkel T, Zabel U, van Zee JM et al. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit. Cell 1992; 68:1121-33.
42. Rice NR, Mackichan ML, Israel A. The precursor of NF-kappa B p50 has I kappa B-like functions. Cell 1992; 78:243-53.
43. Hatada EN, Naumann M, Scheidereit C. Common structural constituents confer I kapppa B activity to NF-kappa B p105 and I kappa B/MAD-3. EMBO J 1993; 12:2781-8.
44. Mercurio F, DiDonato JA, Rosette C et al. p105 and p98 precursor proteins play an active role in NF-kappa B-mediated signal transduction. Genes Dev 1993; 7:705-18.
45. Naumann M, Wulczyn FG, Scheidereit C. The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappaB. EMBO J 1993; 12:213-22.